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Background. Health-related quality of life (HRQoL) impairment is common in pulmonary hypertension (PH), but its clinical
predictors are not well established. This study aims to characterize the HRQoL of patients with pulmonary arterial hypertension
(PAH) and other precapillary forms of PH (pcPH) and to explore its clinical correlates.Materials and Methods. A cross-sectional,
observational study of patients with documented PAH and other forms of pcPH. Patients completed two patient-reported outcome
measures (PROM): Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) and Nottingham Health Profile (NHP).
Clinical characteristics were retrieved from electronic medical records. Results. Mean CAMPHOR and NHP scores for the study
population were indicative of a moderate HRQoL impairment. Patients in World Health Organisation Functional Classes (WHO
FC) III/IV showed significantly worse HRQoL. The main clinical correlates of HRQoL were WHO FC, 6-minute walking distance
(6MWD), and Borg dyspnoea index. Overall quality of life (QoL), assessed through CAMPHOR’s QoL domain, showed patterns
comparable to HRQoL measured by both instruments. Conclusions. HRQoL, measured by two different PROMs, is impaired in
Portuguese patients with PAH and other forms of pcPH, particularly in patients with increased disease severity. WHO FC, 6MWD,
and Borg dyspnoea index are highly correlated with HRQoL and QoL.
1. Introduction
Pulmonary hypertension (PH) encompasses a vast group
of chronic and progressive disorders characterized by an
increase in pulmonary artery pressure, which can be asso-
ciated with a variety of aetiologies [1]. If left untreated, PH
can cause right ventricular failure and, ultimately, death [2–
5]. In clinical practice, several severity and prognosis indi-
cators are usually assessed during patient diagnostic workup
and management, including the World Health Organisation
functional class (WHO FC), 6-minute walking distance
(6MWD), Borg Dyspnoea Index, and several laboratory
biomarkers, which include invasive hemodynamic evaluation
[6–9]. However, these indicators do not provide a direct
estimation of the overall health status and quality of life
(QoL).Therefore, in recent years, there has been an increasing
interest in measuring both health-related quality of life
(HRQoL) and QoL using general or specific-disease patient-
reported outcome measures (PROMs) [10].
Defining the concepts of health status, HRQoL, and QoL
is yet a matter of controversy among experts, which is well
expressed in the medical literature [11]. This leads to the
lack of a standardised terminology, which can introduce sub-
stantial interpretation issues. So, every scientific investigation
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in this field should start by clarifying the criteria used to
define such concepts and, at the same time, by characterizing
the properties and capacities of the instruments used to
evaluate the populations under study. For the purpose of
this study, we define health status as the narrower of the
three concepts, including all aspects of physical, mental, and
social functioning that characterize an individual at a given
time. HRQoL, on the other hand, evaluates the effects of
the physical, mental, and social aspects—and particularly the
effects of illness and treatment—on the individual’s sense of
well-being. QoL is the broader of the three concepts covering
all aspects of life, including non-health-related aspects such
as economic status and social participation, to characterize
an individual’s overall sense of well-being.
In populations with PH, both HRQoL and QoL have
been assessed through various instruments over the years.
Initially, general scales such as the Short-Form 36 (SF-36)
or the Nottingham Health Profile (NHP) were the most
widely used to assess HRQoL; these instruments did not,
however, allow complete QoL evaluation. Recently, a PH-
specific instrument, the Cambridge Pulmonary Hyperten-
sion Outcome Review (CAMPHOR) [12], was developed and
validated for use in various regions, both in clinical practice
and in clinical research settings [13]. CAMPHOR was the
first PH-specific instrument to be developed and it provided
substantial advantages over previously used instruments. It
includes targeted evaluation of PH-specific symptomatology
and activities that allows a better characterization of HRQoL
in the PH population and includes an additional domain
specifically aimed at assessing overall QoL. CAMPHOR was
carefully developed and validated for use in PH populations
with its content derived directly from patients and, thus,
it was widely used over the past decade and is currently
validated for use in several countries [12, 14–17]. More
recently, other PROMs, like emPHasis-10 [18] and PAH-
SYMPACT [19], have also been developed to allow adequate
collection of patient-reported information on health status,
but without the capacity to actually evaluate QoL. Therefore,
CAMPHOR continues to play and important role in PH,
since it is the only PROM that integrates measures of QoL
and provides an actual measure of patient value.
Given the nature of the physiological changes that char-
acterize PH, this condition is expected to impact patient
functionality, HRQoL, and QoL. Actually, several studies
have identifiedHRQoL impairment in varied PHpopulations
[20]. Although the relationships between patient’s clinical
characteristics and HRQoL impairment were not fully elu-
cidated, some clinical factors seem to be highly associated
with these outcomes, includingWHOFC, 6MWD, symptoms
(dyspnoea, fatigue, chest pain), drugs and administration
route, andmental health (anxiety and depression) [2, 20–24].
Still, given the infrequent nature of precapillary forms of PH
and the difficulties in studying these populations, there is still
a need for further data on this field.
On the other hand, althoughwehave a significant number
of studies with various PROMs in these populations [20],
there is yet a lack of scientific evidence about the value of
the retrieved information and about the most efficient and
easy to administer ones. This study aims to characterize the
HRQoL of patients with pulmonary arterial hypertension
(PAH) and other precapillary forms of PH (pcPH) assessed
by a general instrument (NHP) and a disease-specific instru-
ment (CAMPHOR), to evaluate HRQoL impairment and to
explore the correlations between clinical characteristics and
HRQoL measured through these PROMs and, ultimately, to
give insights into the value of such questionnaires in the
global evaluation of patients with these highly debilitating
conditions.
2. Materials and Methods
2.1. Study Design. This is a cross-sectional, observational
study of consecutive patients with documented PAH and
other forms of pcPH (confirmed by right heart catheterisa-
tion) followed at a specialised PH unit at a tertiary care centre
in Northern Portugal (Pulmonary Vascular Disease Unit,
Medicine Department, Centro Hospitalar do Porto, Porto,
Portugal). During the process of CAMPHOR validation
for the Portuguese PH population, patients were asked to
complete two questionnaires aimed at assessing their HRQoL
(CAMPHOR and NHP) and to complete a basic ques-
tionnaire on their demographic and clinical characteristics.
Disease-specific clinical measures, including haemodynamic
ones, were retrieved from the hospital electronic medical
records (EMR).
The study received favourable opinion from the Ethics
Committee of Centro Hospitalar do Porto (Porto, Portugal).
The study protocol and data collection instruments were
submitted and approved by the Portuguese National Data
Protection Commission. All patients provided their written
informed consent prior to inclusion in the study.
2.2. Patient Population. Patients were eligible to participate
in the study if they were ≥18 years old and were able and
willing to give their informed consent. Patients were excluded
if they were unable to complete the study questionnaires
due to illiteracy or cognitive impairment or if their medical
records revealed a medical condition or circumstance that
could compromise their ability to comply with the study
protocol.
2.3. Data Collection and Instruments. HRQoL data were col-
lected by self-administering questionnaires during a sched-
uled routine clinical visit. Participants were asked to com-
plete 3 questionnaires: (1) CHAMPOR, (2) NHP, and (3) a
general demographic/clinical questionnaire, which evaluated
age, gender, race, income, education level, and self-reported
length of PH diagnosis. Clinical and laboratory data were
retrieved from the database of the dedicated EMR software
of the Unit (PAHTool, Inovultus Ltd., Santa Maria da Feira,
Portugal).
2.4. Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR). CAMPHOR was the first questionnaire
specifically validated for PH patients, designed to assess
symptoms, functioning, and QoL in clinical practice and in
clinical trials [12].
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CAMPHOR consists of (1) a 25-item overall symptoms
scale, scored 0–25, with higher scores indicating the presence
ofmore PH symptoms; (2) a 15-item functioning scale, scored
0–30, with lower scores indicating good functioning; and (3)
a 25-item quality of life scale, scored 0–25, with higher scores
indicating poor QoL [12]. The QoL subscale was developed
using the needs-basedmodel [25, 26]; that is, it is based on the
premise that QoL is derived from the ability of the individual
to satisfy his/her needs [12].
The symptom and quality of life scales have dichotomous
response options (“true”/“not true” or “yes”/“no”) while the
functioning scale has three-point response options (“able
to do on own without difficulty”/“able to do on own with
difficulty”/“unable to do on own”).
2.5. Nottingham Health Profile (NHP). NHP is a question-
naire that allows the assessment of the general health status
of a given population, which can be used to assess HRQoL.
NHP comprises 38 items, which fall into six sections: energy
level (3 items), pain (8 items), emotional reactions (9 items),
sleep disturbance (5 items), social isolation (5 items), and
physical mobility (8 items) [27]. Individual items are scored 1
for a “yes” response and 0 for a “no” response.The total score
for each section represents the summation of item scores
expressed as a percentage. For each section, scores range from
0 to 100, with higher scores representing greater perceived
distress (i.e., impaired health status) [27].
2.6. Statistical Analysis. Descriptive data are presented as
mean ± SD or frequency (%). Bivariate analysis correlating
demographic and clinical variables with CAMPHOR/NHP
dimensions scores was conducted using Spearman’s Rank
correlation coefficient (between quantitative variables) and
using point-biserial correlation (between quantitative vari-
ables and binary nominal variables). Multiple linear regres-
sion analysis was conducted only for the significant correla-
tions to identify possible demographic/clinical predictors for
bothCAMPHORandNHP scales.This techniquewas chosen
due to the quantitative nature of the dependent variables.
Significant variables were selected using a stepwise approach
(stepping method criteria: entry, 0.05; removal, 0.10) and
no estimation problems were found. A dummy variable
technique was used to incorporate qualitative independent
variables in the regression models. The assumption of resid-
ual’s normality for the multiple regressions was verified
visually by inspection of the PP plot.
Statistical analyses were conducted with SPSS Statistics
for Windows, version 23.0 (IBM Corp, Armonk, NY, USA),
and results were considered significant if 𝑃 < 0.05.
3. Results
3.1. Study Population Characteristics. A total of 49 patients
accepted to participate in the study and completed the
study questionnaires (𝑁 = 49). Table 1 summarises the
demographic and clinical characteristics of the study pop-
ulation. Mean ± SD age was 50.4 ± 13.7 years and most
patients were female (75.5%). Mean disease duration was
Table 1: Demographic and clinical characteristics of the study
population.
Characteristics PH patients(𝑛 = 49)
Age, years 50.4 ± 13.7
Gender, 𝑛 (%)
Female 37 (75.5)
Male 12 (24.5)
Marital status, 𝑛 (%)
Single 11 (22.4)
Married/divorced/widowed 38 (77.6)
Working status, 𝑛 (%)
Full-time 15 (34.7)
Homemaker 9 (18.4)
Retired 23 (46.9)
Disease duration, months 57.1 ± 58.8
PH aetiology, 𝑛 (%)
PAH and others 37 (75.5)
CTEPH 12 (24.5)
Comorbidities, 𝑛 (%)
Yes 28 (57.1)
No 21 (42.9)
WHO Functional class, 𝑛 (%)
I/II 34 (69.4)
III/IV 15 (30.6)
6MWD, meters 428.0 ± 105.8
Borg dyspnea 2.2 ± 2.6
HR Bas, bpm 78.2 ± 11.6
HR Max, bpm 107.9 ± 19.1
SBP, mmHg 113.4 ± 17.7
DBP, mmHg 68.2 ± 13.6
O2Sat Bas, mmHg 94.0 ± 3.4
O2Sat Min, mmHg 80.5 ± 15.1
NT-proBNP, pg/mL 684.6 ± 908.4
RAP, mmHg 7.1 ± 4.6
mPAP, mmHg 44.8 ± 18.2
PAOP, mmHg 9.8 ± 4.1
CI, L/min/m2 3.1 ± 0.9
PVR, Wood units 7.0 ± 4.3
Diuretics, 𝑛 (%)
Yes 29 (59.2)
No 20 (40.8)
Oral anticoagulants, 𝑛 (%)
Yes 24 (49.0)
No 25 (51.0)
Calcium channel blockers, 𝑛 (%)
Yes 5 (10.2)
No 44 (89.8)
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Table 1: Continued.
Characteristics PH patients(𝑛 = 49)
Oxygen therapy, 𝑛 (%)
Yes 20 (40.9)
No 29 (59.1)
PH specific therapy, 𝑛 (%)
Monotherapy 23 (46.9)
Combination therapy 20 (40.8)
No therapy∗ 6 (12.2)
PH specific therapy route, 𝑛 (%)
Oral 36 (73.5)
Parenteral 7 (14.3)
Data displayed as mean ± SD, except when otherwise indicated; 6MWD:
6-minute walk distance; NT-proBNP: N-terminal pro-brain natriuretic
peptide; Borg: Borg dyspnea score; CI: cardiac index; CTEPH: chronic
thromboembolic pulmonary hypertension; DBP: diastolic blood pressure;
HR Bas: baseline heart rate; HR Max: maximum heart rate; mPAP: mean
pulmonary arterial pressure; PAH: pulmonary arterial hypertension; PAOP:
pulmonary artery occlusion pressure; PVR: pulmonary vascular resis-
tance; RAP: right atrial pressure; O2Sat min: minimum oxygen saturation;
O2Sat bas: baseline oxygen saturation; SBP: systolic blood pressure. ∗No
therapy: CTEPH patients waiting for surgical treatment (𝑛 = 2); Porto-
pulmonary hypertension waiting for liver transplantation (𝑛 = 1). Low
risk congenital heart disease (𝑛 = 2), and idiopathic PAH before specific
therapeutic introduction (𝑛 = 1).
57.1 ± 58.8 months. One or more comorbidities were
present in 57.1% of patients. The most common PH aetiolo-
gies were chronic thromboembolic pulmonary hypertension
(CTEPH) (24.5%), congenital heart disease (22.4%), idio-
pathic/heritable (22.4%), connective tissue disease (14.3%),
and others (16.3%). Others included PAH-associated portal
hypertension and HIV (3 and 1 patients) and 4 patients with
group 5 PH. To allow meaningful statistical analysis, PH
aetiologies are, from this point on, categorised as PAH and
others (including Group 1 PH and Group 5 PH) and CTEPH
(Group 4 PH).
Most patients had PH disease markers compatible with
low (28.6%) or intermediate (53.0%) estimated risk of 1-year
mortality, according to the 2015 ESC/ERS guidelines risk
assessment scale [1]. Most patients were in WHO FC I and II
(69.4%). Mean 6MWD was 428 ± 105.8meters in the overall
population, but it was significantly reduced in patients in
WHO FC III/IV (320.3 ± 99.4 meters) compared to groups
I/II (469.1 ± 75.4meters; 𝑃 < 0.001).
An arterial oxygen desaturation (94.0 ± 3.4 to 80.5 ±
15.1%) during the 6-MWT was found as well as a moderate
elevation of N-terminal pro-brain natriuretic peptide (NT-
proBNP) levels (668.6 ± 908.4 𝜇g/mL). Most of patients
(87.7%) were under PH-specific therapy, 46.9% in monother-
apy and 53.0% in combination therapy. Specific therapy was
predominantly administered through oral route (73.5%). A
substantial number of patients were under oxygen therapy
(40.1.%).
3.2. Health-Related Quality of Life Assessed through CAM-
PHOR and NHP. Overall, the study population showed
mean CAMPHOR scores that were indicative of a moderate
HRQoL impairment: symptoms (9.6 ± 7.7); functioning
(9.3 ± 6.3); quality of life (8.1 ± 7.0). Mean NHP scores
were also indicative of a moderate health-related quality of
life impairment: energy level (27.0 ± 37.2), pain (20.3 ±
31.1), emotional reactions (18.2 ± 18.6), sleep disturbance
(30.2 ± 34.6), social isolation (13.9 ± 24.2), and physical
mobility (26.3 ± 26.2). Importantly, mean scores for both
CHAMPOR and NHP were significantly worse in patients
in WHO FC III/IV, compared to WHO FC I/II (Figure 1).
In patients with WHO FC III/IV, all CAMPHOR domains
showed significantly higher scores, whereas for NHP the
domains showing the worse results were energy level, pain,
and physical mobility. In terms of overall QoL, as measured
through the QoL domain of CAMPHOR, patients showed
comparable patterns, with scores indicative of a moderate
impairment of QoL. CAMPHOR and NHP scores according
to gender, PH aetiology, oxygen therapy, and PH-specific
therapy are explored in Supplementary Materials (available
here).
3.3. Clinical Correlates of Health-Related Quality of Life.
Table 2 explores the relationship between patient demo-
graphic and clinical characteristics and CAMPHOR scores.
In bivariate analysis, WHO FC, 6MWD, and Borg dyspnoea
index were highly correlated with all CAMPHOR domains
(correlation >0.5 or <−0.5, with 𝑃 < 0.001); scatterplots
for high correlations are shown in Supplementary Materials.
Other factors such as age, oxygen use, baseline andmaximum
heart rate, and oxygen saturation were also significantly
correlated with CAMPHOR scores, but with correlations of
lower magnitude. In multivariate analysis only 6MWD and
Borg dyspnoea indexwere consistently associatedwithCAM-
PHOR scores. Interestingly, for the functioning dimension of
CAMPHOR, in multivariate analysis, WHO FC and baseline
heart rate were statistically significant factors, whereas Borg
dyspnoea indexwas not a significant factor for this dimension
only.
Table 3 explores the relationship between patient demo-
graphic and clinical characteristics and NHP scores. The
relationships between NHP scores and patient characteristics
were highly variable between the different dimensions. In
bivariate analysis, WHO FC, 6MWD, and Borg dyspnoea
index were highly correlated with the energy level, pain, and
physical mobility domains of NHP. However, for the emo-
tional reactions and social isolation domains, Borg dyspnoea
index and baseline heart rate were the more relevant factors
in terms of bivariate correlation. Also, the sleep disorders
dimension only showed significant correlation with gender,
Borg dyspnoea index, baseline heart rate, and use of com-
bination therapy, but with correlations of lesser magnitude.
In multivariate analysis, WHO FC and 6WMD remained
significantly associated with NHP scores in the energy level
and physical mobility domains. For the pain domain the sig-
nificant factors were PH aetiology and maximum heart rate,
for the emotional reactions domain the significant factors
were Borg dyspnoea index and baseline heart rate, for sleep
disorders the significant factor was only gender, and for social
isolation the significant factor was only the Borg dyspnoea
index. Nonetheless, linear regression models showed lower
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Figure 1: Mean CAMPHOR and NHP scores according to WHO Functional class. CAMPHOR: Cambridge Pulmonary Hypertension
Outcome Review; NHP: Nottingham Health Profile; WHO FC: World Health Organisation functional class. Error bars represent 95%
confidence intervals. Please note that the upper limit for NHP score is 100; confidence intervals are shown here for illustration purposes.
predictive value (𝑅2 < 0.3) for the pain, sleep disorders,
and social isolation domains (Table 3). Interestingly, clinically
relevant factors such as age, PH aetiology, disease duration,
comorbidities, conservative therapy (including oxygen ther-
apy), or PH-specific therapy did not show particularly strong
correlations with CAMPHOR or NHP scores, especially in
multivariate analyses.
4. Discussion
This study characterized the HRQoL of a cohort of Por-
tuguese PH patients with mostly low to intermediate risk
of estimated 1-year mortality (low disease severity), using
two parallel questionnaires to provide a more comprehensive
assessment of overall patient status. HRQoL was moderately
impaired for the majority of this PH population. Increased
disease severity, assessed by WHO FC, was significantly
associated with greater impairment. Patients in WHO FC
classes III and IV showed significantly higher scores for all the
dimensions of the general and disease-specific instruments,
indicative of important HRQoL impairment.
The PH population included in this study had low disease
severity (approximately 70% of patients in WHO FC I/II),
despite having a mean disease duration over 50 months.
This low disease severity can be explained by the fact that
most patients were under combination PH-specific therapy
at of the time of the study. When compared with other
studies that used NHP and CAMPHOR to assess HRQoL in
PH, our population had substantially lower disease severity.
While most studies included approximately 70% of patients
in WHO FC III/IV [28–32], we included 70% of patients
on the other end of the spectrum (WHO FC I/II). Such a
low profile of disease severity was only previously reported
by one study assessing HRQoL through CAMPHOR in a
population of patients receiving PH-specific treatment [33].
This patient profile of lowdisease severity andmortality risk is
an important distinctive factor for this study, especially in the
current context in which continued treatment innovations
will lead to better treatment outcomes in the future. In a
context of improved vital and clinical outcomes, improving
QoL will be a major treatment goal, thus, studies that
evaluate QoL in low disease severity populations can play
an important role in establishing better strategies to assess
patient outcomes.
CAMPHOR scores in this study were numerically lower
than those reported in previous studies [28–31, 33], but in
some cases the differences are very small, even below 1 point
in theCAMPHORscores. Lower scores are attributable to low
disease severity in this study population. Furthermore, the
significantly higher scores showed by patients in WHO FC
III/IV were comparable to previous findings [31], which fur-
ther validates this relationship between CAMPHOR scores
and disease severity.
In this study mean NHP scores were particularly high
for the dimensions of energy level, sleep disturbance, and
physical mobility (ranging from 25–30%). Scores were also
elevated for pain and emotional reactions (approximately
20%). Together these findings indicate an overall impairment
of HRQoL. A previous study that used the NHP in a PH
population with more severe disease (75% in WHO FC
III/IV) reported substantially higher scores for all NHP
dimensions [32]; NHP scores in our subpopulation of patient
in WHO FC III/IV were comparable to the findings of that
study, which also supports a relationship between disease
severity and NHP scores.
In terms of clinical correlates of HRQoL, the 6MWD
and Borg dyspnoea index were the two factors with stronger
association with CAMPHOR scores, including scores for the
QoLdomain.WHOFCwas also shown to be a highly relevant
factor in bivariate analysis, but since it is intrinsically related
to exercise capacity and dyspnoea, in multivariate analysis
it only reached statistical significance in the functioning
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Table 2: Correlation and multivariate linear regression for the relationship between patient characteristics and CAMPHOR scores.
Characteristics
Symptoms Functioning Quality of life
Correlation
coefficient
Linear regression
coefficient [95%
CI]
Correlation
coefficient
Linear regression
coefficient [95%
CI]
Correlation
coefficient
Linear regression
coefficient [95%
CI]
Age, yrs 0.240 0.403∗∗ 0.283∗
Work status
Full-time −0.172 −0.360∗ −0.166
Homemaker 0.095 0.002 0.064
Retired 0.090 0.342∗ 0.109
Etiology
PAH/others 0.328∗ 0.350∗ 0.333∗
CTEPH
Comorbidities
Yes 0.297∗ 0.228 0.206
No
Functional class
I/II
0.526∗∗∗ 0.627∗∗∗
-
0.505∗∗∗
III/IV 4.74
[1.23; 8.26]
6MWD, meters −0.673∗∗∗ −0.03 −0.742∗∗∗ −0.02 −0.609∗∗∗ −0.03
[−0.05; −0.01] [−0.04; −0.01] [−0.04; −0.01]
Borg dyspnea 0.779∗∗∗ 1.29 0.652∗∗∗ 0.732∗∗∗ 1.19
[0.64; 1.93] [0.59; 1.78]
HR bas, bpm −0.209 −0.299∗ −0.13 −0.301∗
[−0.24; −0.02]
HR Max, bpm −0.338∗ −0.411∗∗ −0.367∗
O2Sat min, mmHg −0.372∗∗ −0.335∗ −0.295∗
Delta O2Sat 0.392∗∗ 0.358∗ 0.333∗
Oxygen use
Yes 0.340∗ 0.330∗ 0.324∗
No
Constant NA 19.11 26.60 16.71
[11.3; 26.9] [16.9; 36.3] [9.5; 23.9]
𝑅2 adjusted NA 0.595 NA 0.527 NA 0.592
For the purpose of brevity only variables with significant results are displayed in the table.The following variables were considered for statistical analysis but did
not reach statistical significance: gender, marital status, disease duration, DeltaHR, SBP, DBP, O2Sat baseline, NT-proBNP, RAP, mPAP, PAOP, CI, PVR, oral
anticoagulants, diuretics, calcium channel blockers, PH-specific therapy, PH-specific therapy route; correlation coefficients calculated using Spearman’s rank
(quantitative versus quantitative variables) or point-biserial (quantitative versus categorical). 𝑅2 adjusted represents the proportion of variability explained
by the proposed model; 6MWD: 6-minute walk distance; NT-proBNP: N-terminal pro-brain natriuretic peptide; Borg: Borg dyspnea score; CAMPHOR:
Cambridge Pulmonary Hypertension Outcome Review; CI: cardiac index; CTEPH: Chronic thromboembolic pulmonary hypertension; DBP: Diastolic blood
pressure; DeltaHR: maximum-baseline heart rate; Delta O2Sat: baseline-minimum oxygen saturation; HR Bas: baseline heart rate; HR Max: maximum
heart rate; mPAP: mean pulmonary arterial pressure; NA: not applicable; NHP: Nottingham Health Profile; NS: not significant; PAH: pulmonary arterial
hypertension; PAOP: pulmonary artery occlusion pressure; PVR: pulmonary vascular resistance; RAP: right atrial pressure; O2Sat min: minimum oxygen
saturation; O2Sat bas: baseline oxygen saturation; SBP: systolic blood pressure; ∗𝑃 < 0.05; ∗∗𝑃 < 0.01; ∗∗∗𝑃 < 0.001.
domain (where Borg dyspnoea index was not a significant
factor). These findings largely agree with previous evidence
that found these three measures to be the most relevant
predictors of HRQoL in PH [2, 23, 24]. NHP scores showed a
more variable relationship with clinical correlates, which was
somewhat expected since NHP evaluated various aspects of
patients’ life in different dimensions. WHO FC and 6MWD
remained themore important correlates for the physical func-
tioning dimensions (energy level and physical mobility), but
for the remaining dimensions linear regression models had
substantially lower predictive value, which could indicate that
variables relevant for these dimensions were not considered
in this study. We hypothesise that some measures of mental
health status could have been important for inclusion in these
BioMed Research International 7
Ta
bl
e
3:
C
or
re
lat
io
n
an
d
m
ul
tiv
ar
ia
te
lin
ea
rr
eg
re
ss
io
n
fo
rt
he
re
lat
io
ns
hi
p
be
tw
ee
n
pa
tie
nt
ch
ar
ac
te
ris
tic
sa
nd
N
H
P
sc
or
es
.
Ch
ar
ac
te
ris
tic
s
N
H
P
En
er
gy
Le
ve
l
Pa
in
Em
ot
io
na
lr
ea
ct
io
ns
Sl
ee
p
di
so
rd
er
s
So
ci
al
iso
lat
io
n
Ph
ys
ic
al
m
ob
ili
ty
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
A
ge
,y
rs
0.
24
1
0.
23
3
0.
04
9
0.
11
5
0.
12
8
0.
30
0∗
G
en
de
r
Fe
m
al
e
−
0.
15
5
−
0.
118
−
0.
21
6
−
0.
30
8∗
-
−
0.
24
1
0.
19
7
M
al
e
−
28
.2
[−
50
.1;
−
6.
3]
W
or
k
sta
tu
s
Fu
ll-
tim
e
−
0.
22
6
−
0.
32
8∗
−
0.
15
2
−
0.
23
9
−
0.
04
6
−
0.
20
1
H
om
em
ak
er
0.
08
2
0.
00
9
0.
20
0
0.
05
0
0.
11
2
0.
00
0
Re
tir
ed
0.
14
6
0.
30
3∗
−
0.
01
2
0.
18
8
−
0.
04
4
0.
18
8
D
ise
as
ed
ur
at
io
n,
m
on
th
s
−
0.
13
4
−
0.
29
4∗
0.
09
4
−
0.
17
9
−
0.
09
8
−
0.
23
9
Et
io
lo
gy
PA
H
/o
th
er
s
0.
34
4∗
0.
35
2∗
-
0.
33
8∗
0.
24
2
0.
25
7
0.
40
9∗
∗
CT
EP
H
27
.2
[9
.4
;4
5.
1]
C
om
or
bi
di
tie
s
Ye
s
0.
29
5∗
0.
20
7
0.
11
6
0.
09
8
0.
17
2
0.
31
0∗
N
o
Fu
nc
tio
na
lc
la
ss
I/I
I
0.
68
6∗
∗
∗
-
0.
55
5∗
∗
∗
0.
30
9∗
0.
16
6
0.
38
2∗
∗
0.
64
9∗
∗
∗
-
II
I/I
V
30
.7
21
.8
[1
1.8
;4
9.6
]
[7.
60
;3
6.
1]
6M
W
D
,m
et
er
s
−
0.
57
8∗
∗
∗
5.
89
−
0.
50
7∗
∗
∗
−
0.
29
3∗
−
0.
18
9
0.
29
1∗
−
0.
74
2∗
∗
∗
−
0.
12
[2
.6
6;
9.1
3]
[−
0.
18
;−
0.
06
]
Bo
rg
dy
sp
ne
a
0.
74
7∗
∗
∗
0.
54
4∗
∗
∗
0.
60
7∗
∗
∗
3.
79
0.
29
6∗
0.
48
8∗
∗
∗
5.
03
0.
61
7∗
∗
∗
[2
.19
;5
.3
8]
[2
.7
5;
7.3
1]
H
R
ba
s,
bp
m
−
0.
117
−
0.
18
7
−
0.
42
7∗
∗
∗
−
0.
42
−
0.
34
1∗
−
0.
40
6∗
∗
−
0.
18
5
[−
0.
78
;−
0.
07
]
H
R
M
ax
,b
pm
−
0.
42
1∗
∗
∗
−
0.
41
0∗
∗
∗
−
0.
43
8
−
0.
17
4
−
0.
15
3
−
0.
21
4
−
0.
29
4∗
[−
0.
84
;
−
0.
04
]
D
elt
aH
R
−
0.
34
6∗
−
0.
29
8
0.
05
8
0.
03
8
0.
02
4
−
0.
20
2
SB
P,
m
m
H
g
−
0.
12
4
−
0.
03
9
−
0.
14
4
−
0.
18
7
−
0.
34
9∗
−
0.
04
1
O
2S
at
m
in
,m
m
H
g
−
0.
28
3
−
0.
23
0
−
0.
28
5
−
0.
02
5
−
0.
27
9
−
0.
35
3∗
D
elt
aO
2S
at
0.
32
3∗
0.
27
1
0.
28
4
0.
03
2
0.
28
0
0.
36
1∗
N
T-
pr
oB
N
P,
pg
/m
L
0.
16
1
0.
13
4
0.
06
3
−
0.
09
4
−
0.
01
2
0.
31
8∗
O
xy
ge
n
us
e
Ye
s
0.
24
2
0.
18
2
0.
20
4
0.
05
7
0.
22
2
0.
32
8∗
N
o
8 BioMed Research International
Ta
bl
e
3:
C
on
tin
ue
d.
Ch
ar
ac
te
ris
tic
s
N
H
P
En
er
gy
Le
ve
l
Pa
in
Em
ot
io
na
lr
ea
ct
io
ns
Sl
ee
p
di
so
rd
er
s
So
ci
al
iso
lat
io
n
Ph
ys
ic
al
m
ob
ili
ty
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t
[9
5%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
C
or
re
la
tio
n
co
effi
ci
en
t
Li
ne
ar
re
gr
es
sio
n
co
effi
ci
en
t[
95
%
CI
]
PH
sp
ec
ifi
ct
he
ra
py
N
on
e
−
0.
02
9
0.
05
3
0.
05
7
0.
10
4
−
0.
00
6
0.
05
8
M
on
ot
he
ra
py
0.
05
8
0.
10
4
0.
01
2
0.
26
8
−
0.
01
8
−
0.
01
1
C
om
bi
na
tio
n
th
er
ap
y
−
0.
04
0
−
0.
14
3
−
0.
05
1
−
0.
34
3∗
0.
02
2
−
0.
02
8
C
on
sta
nt
N
A
N
A
58
.3
N
A
42
.3
N
A
35
.4
N
A
n.
a.
71
.1
[14
.1;
10
2.
4]
[1
3.
5;
71
.0
]
[2
4.
7;
46
.1]
[4
2.
5;
99
.8
]
Ad
ju
ste
d
𝑅
2
N
A
0.
50
4
N
A
0.
21
8
N
A
0.
44
1
N
A
0.
11
3
N
A
0.
29
0
n.
a.
0.
60
2
Fo
rt
he
pu
rp
os
e
of
br
ev
ity
on
ly
va
ria
bl
es
w
ith
sig
ni
fic
an
tr
es
ul
ts
ar
e
di
sp
la
ye
d
in
th
e
ta
bl
e.
Th
e
fo
llo
w
in
g
va
ria
bl
es
w
er
e
co
ns
id
er
ed
fo
rs
ta
tis
tic
al
an
al
ys
is
bu
td
id
no
tr
ea
ch
sta
tis
tic
al
sig
ni
fic
an
ce
:m
ar
ita
ls
ta
tu
s,
D
BP
,D
elt
aB
P,
Sa
tb
as
,R
A
P,
m
PA
P,
PA
O
P,
CI
,P
V
R,
or
al
an
tic
oa
gu
la
nt
s,
di
ur
et
ic
s,
ca
lc
iu
m
ch
an
ne
lb
lo
ck
er
s,
PH
-s
pe
ci
fic
th
er
ap
yr
ou
te
;c
or
re
lat
io
n
co
effi
ci
en
ts
ca
lc
ul
at
ed
us
in
g
Sp
ea
rm
an
’s
ra
nk
(q
ua
nt
ita
tiv
ev
er
su
s
qu
an
tit
at
iv
e
va
ria
bl
es
)o
rp
oi
nt
-b
ise
ria
l(
qu
an
tit
at
iv
e
ve
rs
us
ca
te
go
ric
al
).
𝑅
2
ad
ju
ste
d
re
pr
es
en
ts
th
e
pr
op
or
tio
n
of
va
ria
bi
lit
y
ex
pl
ai
ne
d
by
th
e
pr
op
os
ed
m
od
el
;6
M
W
D
:6
-m
in
ut
e
w
al
k
di
st
an
ce
te
st;
N
T-
BN
P:
N
-
te
rm
in
al
pr
o-
br
ai
n
na
tr
iu
re
tic
pe
pt
id
e;
Bo
rg
:B
or
gd
ys
pn
ea
sc
or
e;
CA
M
PH
O
R:
Ca
m
br
id
ge
Pu
lm
on
ar
yH
yp
er
te
ns
io
n
O
ut
co
m
eR
ev
ie
w
;C
I:
ca
rd
ia
ci
nd
ex
;C
TE
PH
:c
hr
on
ic
th
ro
m
bo
em
bo
lic
pu
lm
on
ar
yh
yp
er
te
ns
io
n;
D
BP
:d
ia
sto
lic
bl
oo
d
pr
es
su
re
;D
elt
aH
R:
m
ax
im
um
-b
as
al
he
ar
tr
at
e;
D
elt
aS
at
:b
as
al
-m
in
im
um
ox
yg
en
sa
tu
ra
tio
n;
H
R
Ba
s:
ba
sa
lh
ea
rt
ra
te
;H
R
M
ax
:m
ax
im
um
he
ar
tr
at
e;
m
PA
P:
m
ea
n
pu
lm
on
ar
ya
rt
er
ia
lp
re
ss
ur
e;
N
A
:n
ot
ap
pl
ic
ab
le
;N
H
P:
N
ot
tin
gh
am
H
ea
lth
Pr
ofi
le
;N
S:
no
ts
ig
ni
fic
an
t;
PA
H
:p
ul
m
on
ar
ya
rt
er
ia
lh
yp
er
te
ns
io
n;
PA
O
P:
pu
lm
on
ar
ya
rt
er
yo
cc
lu
sio
n
pr
es
su
re
;P
V
R:
pu
lm
on
ar
yv
as
cu
la
rr
es
ist
an
ce
;R
A
P:
rig
ht
at
ria
l
pr
es
su
re
;S
at
m
in
:m
in
im
um
ox
yg
en
sa
tu
ra
tio
n;
Sa
tb
as
:b
as
al
ox
yg
en
sa
tu
ra
tio
n;
SB
P:
Sy
sto
lic
bl
oo
d
pr
es
su
re
;∗
𝑃
<
0
.0
5
;∗
∗
𝑃
<
0
.0
1
;∗
∗
∗
𝑃
<
0
.0
0
1
.
BioMed Research International 9
models, since other studies have identified conditions such as
depression and anxiety to be correlated with HRQoL in PH
[21, 22].
This study has limitations inherent to the relatively small
sample size and the less severe disease stage of the studied
patients. Nonetheless, the study is based on high-quality
clinical data, systematically and prospectively collected using
a purpose-designed EMR (PAHTool) at a PH specialised
unit, which further ensures data reliability. Additionally, there
are also limitations associated with the instruments used
to assess HRQoL. Although we used both a general and a
disease-specific instrument to provide amore comprehensive
picture of overall patient status, other instruments (especially
general instruments) could also have been selected. In the
future, HRQoL should be evaluated in large Portuguese
PH populations (eventually in multicentre studies to attain
larger and more diverse samples), employing other highly
used general instruments (such as the SF-36 or EQ50) as
well as the recently developed disease-specific instruments
(emPHasis-10 and PAH-SYMPACT). CharacterizingHRQoL
with these new instruments in larger andmore heterogeneous
populations (in terms of severity) will provide an important
basis for clinical practice assessments and for comparisons
with results from clinical trials. Still, the value of CAMPHOR
as the only disease-specific instrument capable of evaluating
overall QoL should not be understated. While other recently
developed instruments might prove valuable to the clinician,
they are only designed to assess HRQoL and, therefore, do
not demonstrate actually patient value; this can only be
established with an instrument tailored to evaluate QoL, such
as the CAMPHOR. This study highlights the importance of
CAMPHOR as disease-specific instrument of choice when
evaluating HRQoL and QoL in PH patients. It also highlights
some aspects of patients’ lives that are not fully captured by
CAMPHOR (such as mental status) and which should be
considered during HRQoL and QoL assessments.
In conclusion, HRQoL is impaired in Portuguese patients
with PAH and other forms of pcPH, particularly in
patients with increased disease severity. General (NHP) and
disease-specific instruments (CAMPHOR) showed compa-
rable HRQoL impairment in this patient population. CAM-
PHOR also showed a moderate impairment in overall QoL.
WHO FC, 6MWD, and Borg dyspnoea index were highly
correlated with HRQoL impairment in our cohort, as well
as QoL measured through CAMPHOR. In our search for
the “best” and “most” practical PROM to evaluate HRQoL
and QoL in Portuguese PH patients other highly used
general instruments and the newly developed disease-specific
instruments will be tested.
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